Changes in plasma RANKL-osteoprotegerin in a Prospective, Randomized Clinical trial of Initial Antiviral Therapy: A5260s

BACKGROUND: The contributions of the Receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) axis to cardiovascular and bone disease in treated HIV-1 infection is not well-defined. SETTING: Prospective, observational, longitudinal study. METHODS: In a subset analysis of a p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Acquir Immune Defic Syndr
Main Authors: Kelesidis, Theodoros, Moser, Carlee B., Johnston, Elizabeth, Stein, James H., Dube, Michael P., Yang, Otto O., McComsey, Grace A., Currier, Judith S., Brown, Todd T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5997510/
https://ncbi.nlm.nih.gov/pubmed/29533303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001679
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados